In short
Clinical trials are investigating Gt005 in people with geographic atrophy, a form of vision loss linked to age-related macular degeneration. The study data focus on long-term safety, especially in participants who already received Gt005 in earlier Gyroscope studies. The main goal is to see how safe the treatment is over time.
Key points
- Clinical trials of Gt005 are focused on people with geographic atrophy caused by age-related macular degeneration. The main study described is a Phase 1 trial looking at long-term safety after previous treatment with Gt005 in earlier Gyroscope studies. The trial follows participants for up to 5 years after treatment. Researchers are measuring the number and seriousness of eye-related and whole-body adverse events. The study is authorised and plans to enroll 163 participants.
Trial overview
The clinical trial listed for Gt005 is designed to study long-term safety in people with geographic atrophy secondary to age-related macular degeneration. It focuses on participants who were already treated with Gt005 in earlier Gyroscope studies called GT005-01 (FOCUS), GT005-02 (EXPLORE), and GT005-03 (HORIZON).
Who can participate
This study is for participants who have geographic atrophy caused by age-related macular degeneration and who have already received Gt005 in a prior study. In simple terms, it is following people who were treated before, rather than starting with new participants.
What is being measured
The main endpoint is the incidence and severity of ocular and systemic adverse events. Incidence means how often these events happen, and severity means how serious they are. Ocular adverse events are problems that affect the eye, while systemic adverse events affect the whole body.
The study is also described as evaluating long-term safety for up to 5 years after treatment. This means researchers want to learn how safe Gt005 remains over a long follow-up period.
Study design and phase
This is an interventional study, which means researchers are giving a treatment and then observing what happens. The trial is in Phase 1, which is an early stage of clinical testing that mainly looks at safety. The intervention is listed as Drug: PPY988A (subretinal use), which is the study treatment name in the source data.
Trial status and size
The trial status is Authorised. The planned enrollment is 163 participants, meaning the study aims to include 163 people.
Key patient terms
Geographic atrophy is a form of damage in the eye linked to age-related macular degeneration. The macula is the part of the eye needed for clear central vision, so disease in this area can affect reading and seeing faces. A clinical trial is a research study in people that helps doctors learn whether a treatment is safe and useful.